Teva’s migraine drug can’t stop another bad R&D headache as researchers scrap a failed PhIII program for Ajovy
Teva’s marketing horizon for its recently approved migraine drug just got smaller.
The generics company $TEVA with a pipeline, Ajovy’s OK last fall was one …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
